Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Pathai Inc.

Headquarters: Cambridge, MA, United States of America
Year Founded: 2016
Status: Private

BioCentury | May 7, 2024
Deals

Deals report: Novartis strengthens radiotherapy pipeline with pair of deals

Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more
BioCentury | Jun 15, 2023
Management Tracks

Kite’s Huston joins Galapagos as CFO, COO

Plus: Burgess to head BD at Cerevel, and updates from Mablink, PathAI and Berlin
BioCentury | Feb 18, 2023
Management Tracks

CEO Christi Shaw leaving Gilead’s Kite

Plus: MorphoSys’ Lee named CFO at Vir, and updates from Novo Nordisk, PathAI, PhRMA and NORD
BioCentury | Jul 14, 2022
Management Tracks

New CEO at Deerfield-backed Apertura

Plus 10x Genomics hires Wilbur to head commercial, and updates from Immune-Onc, PathAI, Sherlock and more
BioCentury | May 18, 2021
Finance

May 18 Quick Takes: Temasek backs Wilson, Yamada to form G2 Bio; plus PathAI, Interius, Vedere II and more

Singapore-based Temasek will supply $200 million to G2 Management Co. Inc. to foster the development of therapies from the University of Pennsylvania's Gene Therapy Program, led by James Wilson.
Items per page:
1 - 6 of 6